A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis-Reference-Cited by-同舟云学术

A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis

Published:2024-08-15 Issue:9 Volume:103 Page:3573-3583
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Abu-Zeinah Ghaith,Qin Albert,Gill Harinder,Komatsu Norio,Mascarenhas John,Shih Weichung Joe,Zagrijtschuk Oleh,Sato Toshiaki,Shimoda Kazuya,Silver Richard T.,Mesa Ruben

Funder

PharmaEssentia Corporation

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00277-024-05912-8.pdf

Reference62 articles.

1. Barbui T, Thiele J, Gisslinger H et al (2018) The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J 8(2):15. https://doi.org/10.1038/s41408-018-0054-y

2. Mesa RA, Verstovsek S, Cervantes F et al (2007) Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 31(6):737–740. https://doi.org/10.1016/j.leukres.2016.12.0012

3. Tefferi A, Gangat N, Pardanani A, Crispino JD (2022) Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape. Cancer Res 82(5):749–763. https://doi.org/10.1158/0008-5472.CAN-21-2930

4. Kc D, Falchi L, Verstovsek S (2017) The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: A review. Ann Hematol 96(10):1595–1604. https://doi.org/10.1007/s00277-017-3099-2

5. Baumeister J, Chatain N, Sofias AM (2021) Progression of myeloproliferative neoplasms (MPN): diagnostic and therapeutic perspectives. Cells 10(12):3551. https://doi.org/10.3390/cells10123551